​

Pasithea Therapeutics Stock (NASDAQ:KTTA)

OwnershipFinancialsChart
Pasithea Therapeutics by TradingView

Previous Close

$0.58

52W Range

$0.28 - $2.06

50D Avg

$0.73

200D Avg

$0.81

Market Cap

$4.52M

Avg Vol (3M)

$508.48K

Beta

0.25

Div Yield

-

KTTA Company Profile

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Sep 15, 2021

Website

KTTA Performance

KTTA Financial Summary

Dec 24Dec 23Dec 22
Revenue--$486.56K
Operating Income$-14.25B$-15.98M$-14.82M
Net Income$-13.90B$-15.96M$-13.06M
EBITDA$-14.25B$-15.33M$-12.58M
Basic EPS$-12.69K$-12.65$-10.34
Diluted EPS$-12.69K$-13.01$-10.34

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
VIVSVivoSim Labs, Inc.
KALAKALA BIO, Inc.
PLRZPolyrizon Ltd.
VYNEVYNE Therapeutics Inc.
QNRXQuoin Pharmaceuticals, Ltd.
TCRTAlaunos Therapeutics, Inc.
CYCNCyclerion Therapeutics, Inc.